Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.
Adult
Aged
Antibodies, Monoclonal, Humanized
/ pharmacology
CD4-Positive T-Lymphocytes
/ drug effects
Case-Control Studies
Colitis, Ulcerative
/ drug therapy
Female
HIV Infections
/ drug therapy
Humans
Integrins
/ antagonists & inhibitors
Lymphocyte Activation
Male
Middle Aged
Receptors, CCR5
/ metabolism
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
04
2019
accepted:
05
07
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
5
3
2020
Statut:
epublish
Résumé
Anti-α4β7 therapy with vedolizumab (VDZ) has been suggested as possible immune intervention in HIV. Relatively little is known about the α4β7-integrin (α4β7) expression of different T-cell subsets in different anatomical compartments of healthy individuals, patients with HIV or inflammatory bowel disease (IBD). Surface expression of α4β7 as well as the frequency of activation, homing and exhaustion markers of T cells were assessed by multicolour flow cytometry in healthy volunteers (n = 15) compared to HIV infected patients (n = 52) or patients diagnosed with ulcerative colitis (UC) (n = 14), 6 of whom treated with vedolizumab. In addition, lymph nodal cells (n = 6), gut-derived cells of healthy volunteers (n = 5) and patients with UC (n = 6) were analysed. Additionally, we studied longitudinal PBMC samples of an HIV patient who was treated with vedolizumab for concomitant UC. Overall, only minor variations of the frequency of α4β7 on total CD4+ T cells were detectable regardless of the disease status or (VDZ) treatment status in peripheral blood and the studied tissues. Peripheral α4β7+ CD4+ T cells of healthy individuals and patients with UC showed a higher activation status and were more frequently CCR5+ than their α4β7- counterparts. Also, the frequency of α4β7+ cells was significantly lower in peripheral blood CD4+ effector memory T cells of HIV-infected compared to healthy individuals and this reduced frequency did not recover in HIV patients on ART. Conversely, the frequency of peripheral blood naïve α4β7+ CD4+ T cells was significantly reduced under VDZ treatment. The results of the current study will contribute to the understanding of the dynamics of α4β7 expression pattern on T cells in HIV and UC and will be useful for future studies investigating VDZ as possible HIV cure strategy.
Identifiants
pubmed: 31356607
doi: 10.1371/journal.pone.0220008
pii: PONE-D-19-09262
pmc: PMC6663001
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
CCR5 protein, human
0
Integrins
0
Receptors, CCR5
0
integrin alpha4beta7
0
vedolizumab
9RV78Q2002
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220008Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Immunol. 2005 Feb 15;174(4):2343-52
pubmed: 15699171
Science. 1996 Jun 28;272(5270):1955-8
pubmed: 8658171
Sci Transl Med. 2018 Jan 24;10(425):
pubmed: 29367348
Clin Immunol. 2018 Aug;193:24-32
pubmed: 29842945
Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7
pubmed: 29223444
J Virol. 1997 Sep;71(9):6296-304
pubmed: 9261346
Gut. 2015 Jan;64(1):8-10
pubmed: 24946955
J Virol. 1998 Apr;72(4):3351-61
pubmed: 9525662
PLoS Pathog. 2015 Oct 20;11(10):e1005177
pubmed: 26485519
J Immunol. 2000 Nov 1;165(9):5069-76
pubmed: 11046037
Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20877-82
pubmed: 19933330
AIDS. 2019 Mar 15;33(4):F1-F12
pubmed: 30829743
Science. 2006 Nov 17;314(5802):1157-60
pubmed: 17110582
J Infect Dis. 2008 Feb 15;197(4):563-71
pubmed: 18275276
Nat Med. 2016 Jul;22(7):754-61
pubmed: 27239760
PLoS One. 2018 Feb 8;13(2):e0192482
pubmed: 29420608
Sci Immunol. 2017 May 12;2(11):
pubmed: 28763793
Gut. 1995 Oct;37(4):524-9
pubmed: 7489940
Gastroenterol Hepatol (N Y). 2012 Nov;8(11):751-4
pubmed: 24672411
Dig Dis Sci. 2019 Jun;64(6):1651-1659
pubmed: 30835029
Cytometry B Clin Cytom. 2016 Nov;90(6):486-492
pubmed: 26666875
AIDS. 2016 May 15;30(8):1305-8
pubmed: 26891038
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Mucosal Immunol. 2016 Mar;9(2):391-400
pubmed: 26220167
Inflamm Bowel Dis. 2019 Jan 10;25(2):270-282
pubmed: 30165490
Immunity. 2004 Oct;21(4):527-38
pubmed: 15485630
J Immunol. 1994 Oct 15;153(8):3574-83
pubmed: 7930580
PLoS One. 2017 Apr 17;12(4):e0175899
pubmed: 28414780
J Exp Med. 2004 Sep 20;200(6):749-59
pubmed: 15365096
Nature. 2005 Apr 28;434(7037):1093-7
pubmed: 15793563
J Virol. 2011 Feb;85(3):1287-97
pubmed: 21047964
Immunol Rev. 2013 Jul;254(1):54-64
pubmed: 23772614
Sci Transl Med. 2018 Oct 3;10(461):
pubmed: 30282696
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
PLoS One. 2013;8(3):e60094
pubmed: 23527300
Crit Rev Immunol. 2009;29(2):87-109
pubmed: 19496742
J Virol. 2018 Sep 26;92(20):
pubmed: 29976671
Virus Res. 2017 Aug 15;240:107-111
pubmed: 28720421
Gut. 2019 Jan;68(1):25-39
pubmed: 29730603
Nat Immunol. 2008 Mar;9(3):301-9
pubmed: 18264102
Curr Drug Targets. 2013 Nov;14(12):1433-43
pubmed: 23980911
J Pharmacol Exp Ther. 2009 Sep;330(3):864-75
pubmed: 19509315
Mucosal Immunol. 2009 Sep;2(5):439-49
pubmed: 19571800
Blood. 2012 Sep 27;120(13):2610-9
pubmed: 22896005
J Immunol. 2018 Jan 15;200(2):810-820
pubmed: 29196458
J Virol. 2000 Jan;74(1):57-64
pubmed: 10590091
J Autoimmun. 2016 Apr;68:98-104
pubmed: 26873648
J Transl Med. 2011 Jan 27;9 Suppl 1:S2
pubmed: 21284901
Science. 2016 Oct 14;354(6309):197-202
pubmed: 27738167
Science. 1998 Apr 17;280(5362):427-31
pubmed: 9545219
J Immunol. 2013 Sep 1;191(5):2164-73
pubmed: 23894197
J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):345-349
pubmed: 29293157
Clin Exp Immunol. 1993 Jun;92(3):448-54
pubmed: 8099858
J Crohns Colitis. 2017 Aug 1;11(8):903-904
pubmed: 28333273